NASDAQ$GBIO
Generation Bio Co · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Generation Bio's financial position and operational performance were detailed for Q3 2021.
Generation Bio reported a net loss of $31.9 million for Q3 2021, with cash, cash equivalents, and marketable securities totaling $398.4 million as of September 30, 2021. The company highlighted preclinical data demonstrating broad delivery of ceDNA and mRNA to photoreceptors using ctLNP.
- Cash, cash equivalents and marketable securities were $398.4 million as of September 30, 2021.
- Research and development expenses were $22.0 million for the quarter ended September 30, 2021.
- General and administrative expenses were $9.7 million for the quarter ended September 30, 2021.
- Net loss was $31.9 million, or $0.56 basic and diluted net loss per share, for the quarter ended September 30, 2021.
Headline financials
Revenue & EPS history
Generation Bio · Revenue · Quarterly
$1.59M
Revenue by segment
Generation Bio · $2.15M total across 1 segment · Q3 2023
- Collaboration revenue$2.15M—100.0%
Forward guidance
This press release contains forward-looking statements regarding Generation Bio's future expectations, plans, and prospects, including statements about strategic plans, technology platform, research and clinical development plans, the timing of IND submissions and preclinical data, manufacturing plans, and expectations regarding a new facility.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports
+3.8%
Avg return
Earnings day
+5.9%
Avg return
5 days after
+8.6%
Avg return
30 days after
43%
10 / 23 earnings
Positive
+61.7%
Q2 2025
Best reaction
-19.7%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -3.3% | +11.0% | +2.7% | |
| Q2 2025 | +61.7% | +62.0% | +46.9% | |
| Q1 2025 | +4.5% | +0.4% | +4.0% | |
| Q4 2024 | -3.7% | -14.3% | -9.5% | |
| Q3 2024 | +8.7% | -0.5% | -40.8% | |
| Q2 2024 | -2.0% | -3.7% | -10.2% | |
| Q1 2024 | +18.4% | +16.4% | +1.9% | |
| Q4 2023 | +3.1% | +11.5% | +39.4% | |
| Q3 2023 | -1.7% | +7.7% | +46.2% | |
| Q2 2023 | -5.3% | -7.0% | +6.8% | |
| Q1 2023 | -5.0% | -2.7% | +0.4% | |
| Q4 2022 | -8.4% | -10.0% | +15.5% | |
| Q3 2022 | +12.2% | — | — | |
| Q2 2022 | +7.7% | — | — | |
| Q1 2022 | -19.7% | — | — | |
| Q4 2021 | +21.1% | — | — | |
| Q3 2021 | -1.5% | — | — | |
| Q2 2021 | -6.2% | — | — | |
| Q1 2021 | +0.3% | — | — | |
| Q4 2020 | -0.9% | — | — | |
| Q3 2020 | +8.5% | — | — | |
| Q4 2019 | -0.5% | — | — | |
| Q2 2020 | -0.5% | — | — | |
| Q1 2020 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro